博济医药(300404) - 2021 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2021 was ¥55,245,275.36, representing a 165.36% increase compared to ¥20,818,697.66 in the same period last year[8] - Net profit attributable to shareholders was ¥7,369,156.02, a significant turnaround from a loss of ¥5,863,094.83, marking a 225.69% increase[8] - The net profit after deducting non-recurring gains and losses was ¥2,880,893.96, compared to a loss of ¥7,519,974.54, reflecting a 138.31% improvement[8] - Basic earnings per share were ¥0.0325, up 225.00% from -¥0.0260 in the same quarter last year[8] - The company reported a total sales revenue of 12,518,428.88 yuan, accounting for 22.67% of its total operating income[26] - The total operating revenue for the first quarter reached CNY 55,245,275.36, a significant increase from CNY 20,818,697.66 in the previous period[47] - The net profit for the first quarter reached CNY 9,899,292.90, a turnaround from a net loss of CNY 5,698,021.32 in the same period last year[49] - The company's operating profit was CNY 11,126,644.32, compared to an operating loss of CNY 7,242,531.16 in the previous year[49] - The total comprehensive income for the quarter was CNY 10,081,451.44, compared to a loss of CNY 5,485,594.15 in the previous year[50] Cash Flow - The net cash flow from operating activities reached ¥7,490,830.80, a substantial increase of 1,514.39% from -¥529,616.16 in the previous year[8] - The cash inflow from operating activities amounted to CNY 70,467,706.01, an increase from CNY 44,149,562.53 in the previous period, representing a growth of approximately 59.5%[56] - The net cash flow from operating activities was CNY 7,490,830.80, recovering from a negative CNY 529,616.16 in the prior period[57] - The total cash outflow from investing activities was CNY 69,796,489.65, significantly higher than CNY 9,946,990.39 in the previous period, leading to a net cash flow from investing activities of -CNY 11,440,909.02[57] - Cash inflow from financing activities totaled CNY 16,480,000.00, down from CNY 20,115,000.00 in the previous period, resulting in a net cash flow from financing activities of -CNY 5,097,434.12[58] - The ending balance of cash and cash equivalents was CNY 137,507,691.92, compared to CNY 80,808,720.47 at the end of the previous period, indicating a significant increase[58] Assets and Liabilities - Total assets at the end of the reporting period were ¥759,934,380.33, an increase of 1.37% from ¥749,631,868.84 at the end of the previous year[8] - The total liabilities decreased slightly to CNY 263,630,226.54 from CNY 264,636,745.37, indicating a reduction of about 0.38%[41] - The company's equity attributable to shareholders reached CNY 452,929,084.80, up from CNY 444,239,449.04, reflecting an increase of about 1.56%[42] - The total non-current liabilities were CNY 18,723,076.22, with an adjustment of CNY 1,242,203.98 due to the new leasing standards[65] - The company reported a total of CNY 643,680,859.69 in total assets for the first quarter of 2021[68] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 19,132[12] - The largest shareholder, Wang Tingchun, holds 35.57% of the shares, with 60,463,981 shares pledged[12] - Net assets attributable to shareholders increased by 1.96% to ¥452,929,084.80 from ¥444,239,449.04 at the end of the last year[8] Business Operations - The company signed new contracts worth approximately ¥100 million during the reporting period, reflecting a year-on-year growth of about 146%[21] - The company is actively adjusting its business structure in response to potential policy changes in the pharmaceutical industry to mitigate risks[25] - The company is expanding its business into preclinical research and CDMO services, facing competition from established firms in these areas[29] - The company has signed contracts that allow for additional service fees under certain conditions to mitigate risks associated with budget overruns[27] Research and Development - Research and development expenses rose to ¥6,513,359.61, a 32.91% increase, as the company intensified its R&D investments[18] - The company reported a significant increase in other income, totaling ¥5,646,067.64, which is a 174.97% increase due to government subsidies related to daily activities[18] Risk Management - The company is facing risks related to contract execution, including potential delays and terminations due to clinical research failures or changes in client research directions[26] - The company has established a specific responsibility assumption model for project delays to manage risks effectively[28] - The company is enhancing its internal management and operational efficiency to address risks associated with its expanding business scale[29] - The company experienced a credit impairment loss of CNY 1,526,077.90, compared to a reversal of CNY -1,034,789.10 in the previous year, indicating potential credit risk issues[48] Compliance and Standards - The company has not reported any violations regarding external guarantees during the reporting period[34] - The company has implemented the new leasing standards effective January 1, 2021, impacting the financial statements[69] - The first quarter report for 2021 was not audited[70]